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Abstract
Background: Metabotropic glutamate receptors (mGluRs) are ubiquitous throughout the body, especially in brain, where
they mediate numerous effects. MGluRs are classified into groups of which group I, comprising mGluRs 1 and 5, is especially
important in neuronal communication. Group I actions are often investigated with the selective agonist, S-3,5-
dihydroxyphenylglycine (DHPG). Despite the selectivity of DHPG, its use has often led to contradictory findings. We now
report that a particular commercial preparation of DHPG can produce mGluR-independent effects. These findings may help
reconcile some discrepant reports.
Methods: We carried out electrophysiological recordings in the rat in vitro hippocampal slice preparation, focusing mainly
on pharmacologically isolated GABAA-receptor-mediated synaptic currents. Principal Findings: While preparations of DHPG
from three companies suppressed GABAergic transmission in an mGluR-dependent way, one batch had an additional,
unusual effect. Even in the presence of antagonists of mGluRs, it caused a reversible, profound suppression of inhibitory
transmission. This mGluR - independent action was not due to a higher potency of the compound, or its ability to cause
endocannabinoid-dependent responses. Field potential recordings revealed that glutamatergic transmission was not
affected, and quantal analysis of GABA transmission confirmed the unusual effect was on GABA release, and not GABAA
receptors. We have not identified the responsible factor in the DHPG preparation, but the samples were 99% pure as
determined by HPLC and NMR analyses.
Conclusions: In certain respects our observations with the anomalous batch strikingly resemble some published reports of
unusual DHPG effects. The present findings could therefore contribute to explaining discrepancies in the literature. DHPG is
widely employed to study mGluRs in different systems, hence rigorous controls should be performed before conclusions
based on its use are drawn.
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Introduction
The synthetic amino acid S-3,5-dihydroxyphenylglycine
(DHPG) is a potent group-I-selective mGluR agonist [1]that is
widely used in areas of research as diverse as pain [2] cancer
[3], drug abuse [4] and learning [5]. Activation of group I
mGluRs by DHPG affects synaptic transmission in various ways
[6], including the mobilization of endogenous cannabinoids
(endocannabinoids, eCBs [7,8]) and induction of eCB –
mediated forms of short and long term synaptic plasticity
[9,10] by activating the cannabinoid receptor, CB1R. Despite
its extensive use, DHPG sometimes produces controversial
results, leading to variation in its reported potency and the
degree to which antagonists of mGluRs and CB1Rs can oppose
its functional actions, e.g., [11–16]. We have tested the
hypothesis that some commercial preparations of DHPG harbor
a chemical activity that can cause mGluR-independent actions.
We compared the actions of DHPG from three different
companies (Ascent Scientific, Sigma-Aldrich and Tocris Biosci-
ence) on well-established bioassays of mGluR-mediated effects in
the in vitro hippocampal slice. Multiple samples from one batch
of DHPG obtained from Ascent Scientific transiently suppressed
hippocampal GABAergic transmission in an mGluR- and
CB1R-independent manner, whereas another batch from this
source and batches from the other sources did not. We have
not fully identified the contaminant responsible for the
anomalous effects. It could not be distinguished from DHPG
by HPLC, and may have a distinctive signature by proton
NMR. The unrecognized presence of such effects could explain
some controversial findings regarding mGluR control of
synaptic transmission that have been reported. Finally, the
ability of the unknown factor to reduce GABA, but not
glutamate, release suggests that its identification may be of
scientific interest in its own right.
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Comparison of the maximal potency of different batches
of DHPG
We began by comparing the abilities of (S)-3,5 DHPG from
three commercial sources – Ascent Scientific, Tocris, and Sigma-
Aldrich – to suppress inhibitory synaptic transmission to pyramidal
cells in CA1 region of the hippocampal slice. For convenience the
drugs are designated A-DHPG, T-DHPG, and S-DHPG in the
figures. Furthermore, we distinguish between batches Asc-08007-
1-1 and Asc-08116-5-3 from Ascent Scientific; Asc-08007-1-1 was
used throughout the study, except as noted.
Evoked inhibitory postsynaptic currents (eIPSCs) were pro-
duced in CA1 pyramidal cells by stimulating in CA3 in the
presence of 2,3-Dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]quinoxa-
line-7-sulfonamide (NBQX, 10 mM) and D-(-)-2-Amino-5-phos-
phonopentanoic acid (D-AP5, 20 mM), using either KGluconate
(KGluc) - or KCl-based electrode solutions (Materials and
Methods). Responses were evoked continuously at 0.25 Hz
throughout the experiments. The outward eIPSCs recorded with
the KGluc electrodes were smaller than the inward eIPSCs
because of the smaller driving force, but otherwise the recording
conditions were the same.
DHPG was bath-applied at a maximal concentration of 50 mM
for 10 min. All samples of DHPG triggered an initial strong
depression of synaptic activity that recovered only partially after
washout and remained at a reduced level for the duration of the
recordings ($25 min). The peak eIPSC decreases expressed as
percent of baseline eIPSC amplitude occurred during or slightly
after agonist application. Peak decreases were to ,50% of baseline
for T-DHPG and S-DHPG, but were significantly larger (p,0.05),
to ,20% of baseline for Asc-08007-1-1 (Figs. 1B, 1C). The
persistent suppression, called inhibitory long-term depression
(iLTD), was measured at 25 min of washout of DHPG and had
the same properties as previously reported [10]. There were no
significant differences in iLTD magnitude caused by the various
DHPG batches (Fig. 1C).
Effects of mGluR antagonists on different batches of
DHPG
The marked initial depression caused by the Asc-08007-1-1
might be explained by a greater potency of this drug for group I
mGluRs, or perhaps another effect unrelated to mGluRs. To
distinguish among these possibilities, we used potent group I
mGluR antagonists, which have been repeatedly found to block all
actions of DHPG in a variety of settings [13,17–20]. The selective
group I mGluR antagonists, 6-Amino-N-cyclohexyl-3-methylthia-
zolo[3,2-a]benzimidazole-2-carboxamide (YM298198, for
mGluR1) and 2-Methyl-6-(phenylethynyl)pyridine hydrochloride
(MPEP, for mGluR5), completely blocked the effects of T- and S-
DHPG, as no significant eIPSC suppression was observed during
application or washout of DHPG when they were present. Since
the values for S- and T-DHPG do not differ significantly, they
were pooled in Fig. 2A. In contrast, even in the presence of these
group I mGluR antagonists, Asc-08007-1-1 caused a very
substantial depression in peak eIPSC amplitudes, to ,30% of
baseline level. The depression was still present after a 10-min
washout, but not after a 25-min washout (Fig. 2A). Figure 2B
illustrates that the differences between Asc-08007-1-1 and the T-
and S-DHPG can be demonstrated within the same cell. In this
experiment (n=5) all three DHPGs were applied sequentially in
the presence of mGluR antagonists. Only Asc-08007-1-1 sup-
pressed eIPSCs in these conditions. Taken together, the results
suggest that Asc-08007-1-1 has an early, group I mGluR-
independent, suppressive effect on eIPSCs. We considered the
possibility that the residual effect of Asc-08007-1-1 was mediated
by another type of mGluR, and so we also compared its effects in
the presence of the non-selective mGluR blocker (2S)-2-Amino-2-
[(1S,2S)-2-carboxycyclorop-1-yl]-3-(xan th-9-yl) propanoic acid
Figure 1. Comparison of eIPSC suppression caused by DHPG
from different sources. (A) Representative traces showing how
eIPSCs recorded with KGluc-filled electrodes were affected by 10-min
applications of DHPG from Tocris Bioscience (T, left), Ascent Scientific,
Asc-08007-1-1 (A, middle), or Sigma Aldrich (S, right). In this and all
other experiments except those in Fig. 4, S-3,5 DHPG was applied at
50 mM. Black trace = baseline, dashed trace = DHPG, gray trace
=25 min washout. Each trace is the average of ten consecutive
responses. Cal. bars: y:100 pA, x: 50 ms. Results are expressed as percent
of baseline eIPSC amplitudes. (B) Group data obtained with T-DHPG
(white circles) or Asc-08007-1-1 (black circles) DHPG; S-DHPG data were
omitted from the graph for clarity. (C) Summary of peak eIPSC
depressions: T-DHPG: 54.066.7%, n=8, p,0.01; S-DHPG: 51.765.5,
n=8, p,0.01, and Asc-08007-1-1, 18.563.6%, n=5, p,0.001). Late
eIPSC depressions (iLTD) were measured after 25-min DHPG washout
(Wash) period. T-DHPG: 64.468.0%, n=7, p,0.01; S-DHPG: 73.468.2,
n=5, p,0.05, and Asc-08007-1-1, 54.265.6%, n=5, p,0.05). The effect
of Asc-08007-1-1 differed significantly from the others during DHPG
application (asterisk, p,0.05) but not after a 25-min washout.
doi:10.1371/journal.pone.0006122.g001
mGluR-Independent DHPG Effects
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suppression caused by Asc-08007-1-1, implying that the early
transient effect is independent of all mGluRs.
CB1R antagonists do not block actions of Asc-08007-1-1
In view of contradictory reports on the ability of mGluR
antagonists to prevent CB1R-dependent actions of mGluRs (cf
[11,12]), it was important to test the CB1R-dependent effects of
DHPG from another source against those of Asc-08007-1-1. If
Asc-08007-1-1 does mediate transient, mGluR-independent
effects, then it should also mediate transient, CB1R-independent
effects. In confirmation of previous reports, we found that N-
(Piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophen yl)-4-methyl-
1H-pyrazole-3-carboxamide (AM251, 4 mM) or 5-(4-Chlorophe-
nyl)-1-(2,4-dichloro-phenyl)-4-methyl-N-(piperdin-1-yl)-1H-pyr-
azole-3-carboxamide (SR 141716A, 2 mM) completely blocked the
acute effects of T-DHPG on eIPSCs (Fig. 3). Neither short- nor
long-term eIPSC depression occurred. However, in the presence
of a CB1R antagonist, Asc-08007-1-1 caused a significant
transient depression to ,50% of the baseline eIPSC. Again, no
significant depression remained after 25 min of washout (Fig. 3).
Unspecific effects of Asc-08007-1-1 are seen at low
concentrations
We considered that the unexpected effects of Asc-08007-1-1
could be related to the concentration used. Our standard dose,
50 mM, was chosen to be functionally maximal and it seemed
possible that lower concentrations of Asc-08007-1-1 would have
effects that would be fully blocked by mGluR antagonists. To test
this, we compared the effects of Asc-08007-1-1 at concentrations
of 1, 10, 20, and 50 mM, each applied for 5 min, in the presence or
absence of YM298198 plus MPEP, or LY341495 alone (Fig. 4). At
all concentrations .1 mM, Asc-08007-1-1 significantly reduced
eIPSC amplitudes either in the presence or absence of mGluR
antagonists. The antagonists did decrease Asc-08007-1-1 effects, as
concentrations .10 mM were less efficacious (p,0.05) in their
presence than in control solution. Probably the greater variability
of the 10 mM dose in control solution accounts for the lack of
statistically significant antagonism at this concentration. In any
case, the results show that Asc-08007-1-1 has mGluR-antagonist-
resistant effects even at low concentrations.
Only inhibitory synaptic transmission is sensitive to the
unusual action of ASC-08007-1-1
Thus far the data reveal an mGluR- and CB1R-independent
suppression of eIPSCs by Asc-08007-1-1. The question arises as to
the nature of the cellular mechanism by which Asc-08007-1-1
affects synaptic transmission. If it is a general, non-specific block of
a fundamental step in the transmitter release process, then Asc-
08007-1-1 should reduce excitatory synaptic transmission as well.
Figure 2. Inhibition of DHPG-induced iLTD by group I mGluR
antagonists. The selective mGluR1 antagonist, YM298198 (4 mM) and
the mGluR5 antagonist, MPEP (10 mM), were present throughout all
experiments. (A) For display and statistical comparison among groups,
the data from T-DHPG and S-DHPG were pooled (white circles). As no
significant depression was observed with these compounds, recordings
were stopped after 10 min of washout. Peak eIPSC depressions as
percent of baseline for each drug individually (data not shown): T-
DHPG: 95.466.3%, n=5, n.s.; S-DHPG: 93.961.8%, n=3, n.s.; Asc-08007-
1-1: 30.765.2%, n=7, p,0.001. Late eIPSC depressions (after 10 min
washout): T-DHPG: 100.369.8%, n=4, n.s.; S-DHPG: 101.865.6%, n=3,
n.s.; Asc-08007-1-1: 40.664.1%, n=7, p,0.001. After 25-min of
washout, there was no significant depression caused by Asc-08007-1-
1 DHPG (black circles): 85.564.8%, n=7, n.s. Insets: Representative
traces: black trace = baseline, dashed trace = DHPG, gray trace
=25 min washout. Each trace is the average of ten consecutive
responses; KGluc-based electrode solution was used (Materials and
Methods). Cal. bars: y:100 pA, x: 50 ms. (B) Continuous recorder trace
showing the effects of T-DHPG, S-DHPG, and Asc-08007-1-1 DHPG
sequentially applied, after washout of the previous appolication, to the
same cell. A KCl-based electrode solution was used, so the eIPSCs are
downward deflections that appear as straight lines at this time
resolution. One-s voltage steps were given every 90 s to elicit Ca
2+
influx through voltage-gated Ca
2+ channels (VGCCs) and DSI [13], which
appears as the transient reductions of eIPSCs. For display purposes, a
small portion of the trace is omitted after each drug’s washout. Note
the strong remaining effect of Asc-08007-1-1, compared to the lack of
effect of T-DHPG and S-DHPG. Cal. bars: y: 200 pA, x: 1 min.
doi:10.1371/journal.pone.0006122.g002
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mediated largely by AMPARs in CA1 s. radiatum. NBQX and AP5
were absent and mGluR antagonists YM298198 and MPEP were
present in these experiments. After a 5-min application of Asc-
08007-1-1 (50 mM) the field potentials showed evidence of
hyperexcitabilityintheformofpopulationspikepotentialoscillations
on the wave. The fEPSP amplitudes appeared to be decreased (to
88.960.9% of baseline, p,0.05, n=5; Fig. 5A), but this is probably
attributable to interference from the population spikes. The slope of
the fEPSP (measured at 1–1.5 ms after the fiber volley) on the other
hand,didnotchangeduringAsc-08007-1-1application(98.561.5%
of baseline, n=5). The apparent lack of effect on the excitatory
synapsesthemselves,togetherwiththeincreaseinexcitabilityseenin
the repetitive population spike discharge could be explained by a
selective effect on inhibitory transmission. The hyperexcitable state
made it difficult to examine excitatory synaptic responses directly,
however. We therefore recorded field potentials in the presence of
the GABAA channel blocker, 6-Imino-3-(4-methoxyphenyl)-1(6H)-
pyridazinebutanoicacidhydrobromide(gabazine,20 mM).Forthese
experiments,theCA3regionwasremovedfromthesliceandinsome
cases small amounts of ionotropic GluR antagonists were used to
reduce hyperexcitability (Materials and Methods). If Asc-08007-1-1
increases excitability only by suppressing inhibition, then it should
have no effect when GABAergic synapses are blocked. We found
that, indeed, in the presence of gabazine and group I mGluR
antagonists Asc-08007-1-1 had no significant influence on the
amplitudes (9760.9% of baseline, n=7) or the slope (94.762.7% of
baseline, n=7; Fig. 5B). It appears that the mGluR- and CB1R-
independent effects of Asc-08007-1-1 only affect GABAergic
synapses.
The unexpected effects of Asc-08007-1-1 target GABA
release
Since it does not affect excitatory transmission, Asc-08007-1-1
probably affects eIPSCs by a postsynaptic action on GABAARs or
a presynaptic effect on GABA release. To distinguish between
these possibilities, we switched to a strontium (Sr
2+)-substituted
[21–24] extracellular solution. Replacing extracellular Ca
2+ with
Sr
2+ causes copious asynchronous quantal release of GABA
(mIPSCs) after stimulation of inhibitory interneurons [24] (Fig. 6A).
Quantal analysis of release can then be done by counting evoked
mIPSCs and measuring their amplitudes. To control for the
sporadic occurrence of spontaneous (not evoked) mIPSCs, which
could conceivably confound the analysis, we also measured
mIPSCs occurring in a 150-ms window prior to the stimulus.
These ‘background’ mIPSCs (Fig. 6B) were not altered by Asc-
08007-1-1, indicating that any measured changes in evoked
mIPSCs were not contaminated by the background events.
Application of the Asc-08007-1-1 for 5 min significantly decreased
the frequency of evoked asynchronous mIPSCs (p,0.05, n=7)
during drug application; a 10-min washout was accompanied by
partial recovery (p,0.05; Fig. 6B). Amplitude distributions were
assessed via cumulative frequency plots followed by K-S tests. In
contrast to the consistent reduction of mIPSC frequency in all
cells, in 6 of 7 cells there was no significant reduction in the
distribution of evoked asynchronous mIPSC amplitudes (e.g.,
Fig. 6C). We conclude that Asc-08007-1-1 reduces GABA release.
Figure 4. Concentration-response curves for Asc-08007-1-1
DHPG. Concentration-response curves in the presence (black circles) or
absence (white circles) of mGluR antagonists (YM298198 plus MPEP, or
LY341495 alone). Peak eIPSC amplitude depressions expressed as
percent of baseline. Depression caused by all DHPG concentrations
.1 mM are significant (p,0.01) in the presence and absence of
antagonists. White circles: 1 mM: 89.962.5%, n=4; 10 mM: 64.967.6%,
n=6; 20 mM: 38.864.3%, n=6; 50 mM: 18.862.7%, n=4. Black circles:
1 mM 96.463.3%, n=4; 10 mM: 80.064.2%, n=5; 20 mM: 63.861.3%,
n=6; 50 mM: 31.363.3%, n=6. The difference between the depressions
observed in the presence or absence of antagonists is significant for
concentrations .10 mM( p ,0.05).
doi:10.1371/journal.pone.0006122.g004
Figure 3. Inhibition of iLTD by CB1R antagonists. AM251 or
SR141716A was present throughout all experiments. T-DHPG (T, white
circles), Asc-08007-1-1, A, black circles). As T-DHPG caused no significant
depression, recordings were stopped after 10 min of washout. Insets
show representative traces for each condition. Black trace = baseline,
dashed trace = DHPG, gray trace =25 min washout. Each trace is the
average of ten consecutive responses. Peak eIPSC depression expressed
as percent of baseline: T-DHPG 98.365.3%, n=7, n.s.; Asc-08007-1-1:
53.668.7%, n=6, p,0.01. Late eIPSC depressions (10-min washout); T-
DHPG: 99.868.3%, n=6, n.s.; Asc-08007-1-1: 57.567.6%, n=6, p,0.05.
Peak eIPSC was not significant from baseline after a 25 min washout of
Asc-08007-1-1: 85.862.1%, n=4, n.s. Cal. bars: y:100 pA, x: 50 ms.
doi:10.1371/journal.pone.0006122.g003
mGluR-Independent DHPG Effects
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mGluR-independent effects
To determine if the unusual actions of Ascent Scientific
DHPG were unique properties of batch Asc-08007-1-1, or if they
are common to all DHPG samples from this company, we tested
batch Asc-08116-5-3 as well. In this series of experiments the
slices had been pretreated in 300 nM v-agatoxin IVA (agatoxin),
to block GABA release from interneurons that release through
P/Q type VGCC and do not express CB1Rs. As eCBs primarily
inhibit release from interneurons that release GABA through N-
type VGCC [25], agatoxin increases the relative contribution of
GABA release from eCB-sensitive interneurons [26,27], and thus
provides a more sensitive assay for possible anomalous effects on
these cells. We observed that, whereas group I mGluR
antagonists YM298198 and MPEP fully blocked the effects of
Asc-08116-5-3, Asc-08007-1-1 continued to reduce the eIPSCs to
,28% of baseline values (p,0.01). The effects of T-DHPG and
S-DHPG (Fig. 7) were also abolished by mGluR antagonists.
This indicates that the factor responsible for mGluR-independent
effects is not a universal property of (S)-3,5 DHPG from Ascent
Scientific, but thus far has only been found in multiple samples
from one batch.
Chemical analysis of DHPG
The data point to an mGluR- and CB1R-independent property
of Asc-08007-1-1 that affects GABA release. One possibility is that
there is a chemical factor in Asc-08007-1-1 that is responsible.
Although a thorough chemical analysis of Asc-08007-1-1 was
beyond the scope of this investigation, we did obtain both HPLC
and proton NMR comparisons of T-DHPG, S-DHPG, Asc-
08007-1-1, and Asc-08116-5-3. All analyses were carried out
‘‘blind’’; i.e., the technicians had only a series of coded and
otherwise unmarked samples. The code was broken by the authors
after the analyses had been performed. The HPLC analysis was
carried out by Ascent Scientific laboratory. By HPLC, samples of
(S)-DHPG from all sources were essentially identical (data not
shown). They were $98% pure; the racemate, (R)-DHPG
constituted a small contaminant that was present in all samples,
indicating that it could not account for the unusual effects. We also
obtained proton-NMR spectra from the NMR facility at the
University of Maryland School of Medicine. Two independent
runs were done, and T-DHPG, S-DHPG, Asc-08116-5-3, and two
different samples of Asc-08007-1-1, were tested. Unique, irregular
minor peaks indicative of contaminants or impurities were present
in all samples in the range from 0 to 4.8 ppm (data not shown).
Figure 5. Asc-08007-1-1 DHPG does not affect fEPSPs in the presence of mGluR antagonists and gabazine. Traces in (A) and (B) show
representative fEPSPs for each condition; NBQX and AP5 absent, and YM298198 and MPEP present for all experiments. Each trace (black = baseline,
dashed = DHPG) is the average of 10 responses. (A) Left graph: raw amplitude measurement of fEPSPs before (control, n=5) or during Asc-08007-1-1
application (DHPG, n=5). Right graph: raw slope measurement of fEPSPs before (control, n=5) or during DHPG application (DHPG, n=5). (B) Same as
in (A), but fEPSPs were recorded in the presence of gabazine, 20 mM. Left graph: raw amplitude measurement of fEPSPs before (control, n=7) or
during Asc-08007-1-1 application (DHPG, n=7). Right graph: raw slope measurement of fEPSPs before (control, n=7) or during Asc-08007-1-1
application (DHPG, n=7, n.s.). Cal. bars: y: 0.1mV, x: 10 ms. Asterisk: significant difference, p,0.05, paired t-test.
doi:10.1371/journal.pone.0006122.g005
mGluR-Independent DHPG Effects
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the Asc-08007-1-1 sample from all other samples, including Asc-
08116-5-3 (Fig. 8). Relative to the tetramethylsilane (TMS)
reference signal at zero, the four doublets (perhaps a doublet of
doublets) have chemical shifts of between 7.2 and 8.2 ppm. The
doublet peaks appear to be correlated, suggesting they may be part
of the same molecule. If they do represent one molecule, then
estimating its relative abundance by integrating the areas under
the peaks, and comparing the sum to the integrated peak areas
associated with DHPG, suggests that this molecule could account
for ,1% of the sample. We do not know the identity of the
molecule or indeed if it has any relationship to the anomalous
properties of Asc-08007-1-1.
Discussion
A batch of the widely used selective group I agonist, (S)-3,5
DHPG, Ascent Scientific Asc-08007-1-1, causes a major, revers-
ible, suppression of GABAergic synaptic transmission that is
Figure 7. Asc-08116-5-3 DHPG does not cause mGluR-inde-
pendent effects. Representative traces (top) and pooled data
(bottom) showing the effects of 50 mM Asc-08116-5-3 DHPG for 5 min
on eIPSCs in slices pretreated in v-agatoxin IVA (300 nM) and YM298198
plus MPEP. Traces (black = baseline, dashed = DHPG) are represen-
tative averages of 10 consecutive responses in each condition. Peak
eIPSC amplitude depressions expressed as percent baseline amplitudes:
Asc-08007-1-1(A-007): 28.565.9%, n=5; T-DHPG (T): 80.2610.0%, n=4;
S-DHPG (S): 85.364.9%, n=3; Asc-08116-5-3 (A-116): 86.266.1%, n=6.
Asterisk: significant difference from baseline responses, p,0.05. Cal.
bars: y:200 pA, x: 100 ms.
doi:10.1371/journal.pone.0006122.g007
Figure 6. Asc-08007-1-1 DHPG reduces frequency but not
amplitude of asynchronous, evoked mIPSCs in the presence of
mGluR antagonists. (A) Representative traces showing stimulation-
evoked, asychronous mIPSCs in control conditions (Sr
2+-substituted
bathing solutions for all experiments; see Materials and Methods) (C), in
DHPG (D) and after 10 min. of washout (W). Cal. bars: y: 13 pA, x: 40 ms.
(B) Numbers of asynchronous evoked mIPSCs (white bars; counted in
31 traces per cell within a 150-ms window beginning 200 ms after a
field stimulus in s. radiatum). Gray bars: frequency of spontaneous
mIPSCs measured before stimulation (background). Events were
counted in control condition (C), during DHPG application (D) and
DHPG washout (W). Numbers of evoked mIPSCs (n=6 cells); control:
30.265.6, DHPG: 21.265.9, Wash: 22.265.6. Numbers of background
mIPSCs (same cells): control: 16.363.4 DHPG: 13.663.2; Wash: 14.566.4.
Asterisks: significant differences from control evoked responses,
p,0.05. No other groups differed by ANOVA followed by multiple t-
tests. (C) Cumulative frequency of the amplitude distribution of evoked
mIPSCs from one cell – control = white circles, DHPG = black circles,
wash = gray triangles. Results typical of 6 of 7 cells analyzed. Inset:
Average of superimposed traces (n=53) of evoked mIPSCs before
(control) and during DHPG application - C: Control, D: DHPG. Cal. bars: y:
8.6 pA, x: 13 ms.
doi:10.1371/journal.pone.0006122.g006
mGluR-Independent DHPG Effects
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hands, the action is not shared by preparations of the same drug
from other companies, or by a different batch from Ascent
Scientific. The observations are important because they reveal that
a preparation of a widely used selective group I mGluR agonist
that is ,99% pure by HPLC and NMR can have pronounced
non-specific effects. Moreover, the resemblance between our
observations and published reports of anomalous mGluR agonist
effects of DHPG suggests that our data could help reconcile the
contradictory observations if the enigmatic action of DHPG were
occasionally to be found in preparations from other sources.
Among the controversial results are those pertaining to the
mobilization of eCBs by mGluRs, an area of intense current
research interest. Finally, in pointing to the existence of a factor
that selectively reduces GABA release without affecting glutamate
release, the data could lead to discovery of novel regulators of
transmitter release.
DHPG is a selective group I mGluR agonist [28]. (S)-(+)-a-
Amino-4-carboxy-2-methylbenzenacetic acid (LY367385) and
MPEP are selective antagonists of mGluR1 and mGluR5,
respectively, that in combination generally inhibit all effects of
DHPG. However, antagonist-resistant DHPG actions have been
reported. Activation of group I mGluRs can mobilize eCBs in
hippocampus [8] and cerebellum [7]. However, some data show
that while bath-applied DHPG rapidly suppresses eIPSCs,
pretreatment of slices with a CB1R antagonist only reveals a
reduction of eIPSC suppression after $10 min of DHPG
treatment (e.g. [11][19], Figs. 5C, 8B). DHPG must have reduced
the eIPSCs by a CB1R-independent mechanism prior to this time.
The results [11] would also suggest that the CB1R-independent
suppression of IPSCs is caused by DHPG, but not by synaptically-
released glutamate ([11], Figs. 4A, 5C). CB1R-independent effects
like this are not always seen, however [7,8,12]. These discrepan-
cies could be explained if an unrecognized mGluR- and CB1R-
independent factor transiently suppressed eIPSCs and occluded
the actual mGluR- and CB1R-dependent actions of DHPG.
Unfortunately, it is not reported whether or not mGluR
antagonists inhibited the DHPG-mediated responses [11], so this
inference remains unverified.
Volk et al. [15] show that, although the combination of
LY367385 and MPEP abolishes DHPG-induced LTD of fEPSPs
as well as the phosphorylation of ERK, the antagonists leave
untouched a large, transient, DHPG-induced fEPSP depression.
The magnitude and time course of this antagonist-resistant effect
are essentially identical to the anomalous IPSC suppression that
we observe. Volk et al. [15] used either R,S- or S-DHPG obtained
from Tocris, suggesting the possibility that effects like those seen
with Asc-08007-1-1 are not unique, but may be associated with
preparations from other sources. Note, however, that in our hands
Asc-08007-1-1did not affect glutamatergic transmission.
We observe that the mGluR antagonist-resistant early eIPSC
suppression caused by Asc-08007-1-1 is followed by the mGluR-
and CB1R-antagonist-sensitive iLTD that is normally produced
Figure 8. Distinctive peaks in proton NMR spectrum of Asc-
08007-1-1 DHPG. Segments of 1D proton NMR spectra derived from
samples of Asc-08007-1-1 (A-007), Tocris DHPG, Sigma DHPG, and Asc-
08116-5-3 (A-116). The samples were prepared in D2O and the x-axis
shows the chemical shifts in parts per million (ppm) with respect to the
tetramethylsilane (TMS) reference signal at zero. The most striking
difference between Asc-08007-1-1 and all other samples is the series of
4 doublets between about 7.2 and 8.2 ppm. The arrow in the top trace
shows an enlargement of one of the doublets. Various organic
molecules have chemical shifts in the range of 7.2 to 8.2 ppm, but
the one responsible for the doublet pattern has not been identified. Not
shown are the regions of the spectra between 0 and the water peak at
4.8 ppm in which irregular sequences of peaks were found in all
samples. Each irregular sequence appeared to be unique for each
preparation and did not obviously distinguish Asc-08007-1-1 from the
others.
doi:10.1371/journal.pone.0006122.g008
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Similarly mGluR-dependent LTD is produced as usual after the
early mGluR- or CB1R-independent phase in other work [11,15].
In other words, even when DHPG samples do produce anomalous
effects, they retain their expected efficacy at group I mGluRs. In
our case, this is not surprising: Asc-08007-1-1 resembled all other
compounds in HPLC and proton NMR analyses. Thus the
anomalous effects must be attributed to an additional action,
rather than an entirely different one. We do not know the origin of
the additional activity. The HPLC results and the series of doublet
peaks found uniquely in the proton NMR analysis of Asc-08007-1-
1 are the only clues. If this contaminant is responsible, it must be
quite potent in antagonizing GABA release, since by both
chemical assays the purity of Asc-08007-1-1 is ,99%. Given the
broad use of DHPG in diverse areas of research, proper care must
be taken to verify its specificity.
Materials and Methods
Animal Treatment and slice preparation
Ethics Statement. All animal handling work was conducted
in accordance with national and international guidelines. All
animal handling protocols were reviewed and approved by the
University of Maryland School of Medicine IACUC. The number
of animals used was minimized, and all necessary precautions were
taken to mitigate pain or suffering. Five- to seven-week old
Sprague–Dawley (Charles River) rats were deeply sedated with
isoflurane and decapitated. Slices, 400-mm-thick, were cut on a
Vibratome (model VT1200s Leica Microsystems) in an ice-cold
bath solution and then stored at room temperature for 1 h before
transfer to the recording chamber (RC-27L, Warner Instruments,
CT, USA) at 30uC. The extracellular recording solution contained
(in mM) 120 NaCl, 3 KCl, 2.5 CaCl2, 2 MgSO4, 1 NaH2PO4,2 5
NaHCO3, and 20 glucose, and was bubbled with 95%O2, 5%CO2
(pH 7.4). Ionotropic glutamate responses were blocked with 2,3-
Dioxo-6- nitro-1,2,3,4-tetrahydrobenzo[f]quinoxaline-7-
sulfonamide (NBQX, 10 mM) and D-(2)-2-Amino-5-
phosphonopentanoic acid (D-AP5, 20 mM). When they were
used, the mGluR antagonists were bath-applied at the following
concentrations: YM298198 – 4 mM, MPEP – 10 mM, LY341495 –
100 mM.
Electrophysiology
Whole-cell pipettes were pulled from thin wall glass capillaries
(1.5 O.D., World Precision Instruments, Florida, USA). They
contained (in mM) either 146 KGluconate (KGluc), 1 NaCl, 1
MgSO4, 0.2 CaCl2, 2 EGTA, 10 HEPES, 4 MgATP, 0.3 tris
GTP, or 90 CsCH3SO4, 1 MgCl2, 50 CsCl, 2 MgATP, 0.2 Cs4-
BAPTA, 10 HEPES, 0.3 Tris GTP and 5 QX314. Electrode
resistances in the bath were 3–6 MV. If the series resistance, when
checked by a –5mV step, changed significantly (,20%), the data
were discarded. In recordings done with the KGluc-based
electrode solution, pyramidal cells from the CA1 hippocampal s.
pyramidale region were clamped at a holding potential of –50 mV.
In experiments with the KCl-based electrode solution cells were
held at 270 mV. Monosynaptic eIPSCs were elicited by 200-ms-
long extracellular stimuli delivered at 0.25 Hz with concentric
bipolar stimulating electrodes placed in s. radiatum. Data were
collected using either an Axopatch 200B or an Axopatch 1C
amplifier (Molecular Devices, Pennsylvania, USA), filtered at
2 kHz and digitized at 5 kHz using a Digidata 1322 (Molecular
Devices) and Clampex 9.0 (Molecular Devices).
Asynchronous mIPSCs were recorded in the whole cell
configuration described above with the KCl-based intracellular
solution. After breaking into a cell, the extracellular solution was
changed to one containing 4 mM MgSO4 and 4 mM strontium
(Sr
2+) instead of Ca
2+. The amplitude and frequency of
asynchronous sIPSCs that followed an evoked IPSC were
measured 200 ms after the stimulation artifact, during a 150 ms
windows for each trace (to obtain a sufficient number of events,
data was gathered from 31 traces per condition), following the
procedures of Morishita et al [24].
For experiments involving field excitatory postsynaptic poten-
tials (fEPSPs), patch electrodes were filled with 2 M NaCl. The
fEPSPs were recorded in s. radiatum, between CA3 and subiculum.
Extracellular stimulation was given at 0.05 Hz with a bipolar
electrode located in either s. radiatum near CA3 or subiculum. When
fEPSPs were recorded in the presence of gabazine, the CA3 area
was cut off to prevent the development of spontaneous
epileptiform activity. In some cases, the extracellular solution
was also changed to one containing, in mM: 120 NaCl, 2.4 KCl, 6
MgSO4, 1 NaH2PO4, 25 NaHCO3, 20 glucose, 1.5 CaCl2, as well
as AP5 10 mM and NBQX 0.01 mM, which helped suppress
hyperexcitability. When tested without gabazine, this extracellular
solution did not to affect our basic results.
Chemicals
(S)-3,5 DHPG was obtained from Tocris Bioscience (Missouri,
USA) batch 26, Sigma-Aldrich (Missouri, USA), batch
087k46202, and Ascent Scientific (Bristol, UK), batches Asc-
08007-1-1 and Asc -08116-5-3. All drugs were made up as
1000X stocks in distilled water (except for AM251 and
SR141716, which were made at a 10000X concentration in
DMSO) as soon as they were obtained. Stocks were immediately
divided into 20 mL aliquots and frozen at 220uC until use.
Once thawed, aliquots were either used or discarded; none were
refrozen and reused. Care was taken to see that all samples were
handled identically, and were used within two months after
preparation. AM251 and stocks were dissolved in DMSO. Final
concentration of DMSO in the bath was 0.01%. Drugs were
obtained from Tocris Bioscience (AM251, MPEP, SR95531, and
LY341495), Ascent Scientific (NBQX, AP5, and YM298198),
and NIDA (SR141716). All other drugs and chemicals were
purchased from Sigma-Aldrich.
Data Analysis
Statistical tests among groups were done with one-way ANOVA
with repeated measures (two way ANOVA for the data presented
in Fig. 1) followed by a Student- Newman-Keuls (SNK) test
(SigmaStat). Paired t tests were used for single comparisons. The
significance level for all tests was p,0.05 (*), except the
Komolgorov-Smirnov (K-S) tests in Fig. 7 where the significance
level was 0.005. Group mean6SEMs are shown for display
purposes. Measurements of mIPSC frequency and amplitude
(Fig. 6) were performed with the Mini Analysis Program
(Synaptosoft, New Jersey, USA). For comparison of cumulative
amplitude distributions (mIPSCs experiments) we used the
Kolmogorov-Smirnov test, available at http://www.physics.
csbsju.edu/stats/KS-test.n.plot_form.html. In Figures 1–3 the
group data for experimental time courses were smoothed by
running averages (n=10), and incremental sampling (n
th =10) in
SigmaPlot 11.0.
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